Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.
- First Posted Date
- 2006-05-26
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1189
- Registration Number
- NCT00330460
Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer
Phase 2
Completed
- Conditions
- Metastatic Colorectal Cancer
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2009-09-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 50
- Registration Number
- NCT00327119
An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density
- First Posted Date
- 2006-05-12
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Amgen
- Target Recruit Count
- 200
- Registration Number
- NCT00325468
Observational Safety Study of Etanercept (Enbrel) for Treatment of Psoriasis
- First Posted Date
- 2006-05-08
- Last Posted Date
- 2018-06-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 2511
- Registration Number
- NCT00322439
Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer
Phase 1
Completed
- Conditions
- Locally Recurrent and Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2006-05-05
- Last Posted Date
- 2013-07-31
- Lead Sponsor
- Amgen
- Target Recruit Count
- 46
- Registration Number
- NCT00322400
Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer
- First Posted Date
- 2006-05-04
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1904
- Registration Number
- NCT00321620
Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents
Phase 2
Completed
- Conditions
- MDSThrombocytopeniaMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2006-05-04
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 69
- Registration Number
- NCT00321711
A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 2049
- Registration Number
- NCT00321464
A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease
- First Posted Date
- 2006-03-23
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 436
- Registration Number
- NCT00306215
- Locations
- 🇦🇺
The Alfred Hospital, Prahran, Victoria, Australia
🇦🇹Krankenanstalt Rudolfstiftung, Wien, Austria
🇨🇦Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada
A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects
Phase 2
Completed
- Conditions
- Osteoporosis
- Interventions
- Drug: 14 mg AMG 162Drug: 100 mg AMG 162Drug: 60 mg AMG 162Drug: Placebo
- First Posted Date
- 2006-03-23
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 212
- Registration Number
- NCT00306189
© Copyright 2025. All Rights Reserved by MedPath